News | Breast Imaging | September 21, 2020

Spotting Breast Cancer's Spread to the Brain Before Symptoms Could Improve Survival

Breast cancer patients whose disease has spread to their brains fare better if their metastases are picked up before they begin to cause symptoms, according to a study presented at the 12th European Breast Cancer Conference.

Getty Images

September 21, 2020 — Breast cancer patients whose disease has spread to their brains fare better if their metastases are picked up before they begin to cause symptoms, according to a study presented at the 12th European Breast Cancer Conference.

Breast cancer that spreads to the brain is becoming more common and it is one reason why the disease becomes untreatable. However, asymptomatic brain metastases can be identified with an magnetic resonance imaging (MRI) scan and the new research suggests that doing so could mean less aggressive treatment and a longer survival time.

Patients with other forms of cancer that tend to spread to the brain, such as lung cancer, are already given a brain scan when they are first diagnosed. The researchers say a clinical trial of brain scans for breast cancer patients who are at high risk for developing brain metastases is warranted.

The study was presented by Elena Laakmann, M.D., from the department of gynaecology at the University Medical Center Hamburg-Eppendorf in Germany. She said: "The prognosis for patients with breast cancer that has spread to the brain is poor, and survival for these women hasn't improved over the last few decades. We do not currently test for asymptomatic brain metastases in breast cancer patients, although this does happen in some other types of cancer.

"In this study we wanted to find out more about breast cancer that has spread to the brain and in particular to see whether there might be any advantage to spotting brain metastases before the development of neurological symptoms."

The researchers investigated a group of 2,589 German patients who were diagnosed with breast cancer that had already spread to their brains between 2000 and 2019. Of these, 2,009 patients had already experienced symptoms of brain metastases (such as headache, impaired vision, nausea or seizure), while the remaining 580 women had no symptoms of brain metastases and were only diagnosed by chance.

When researchers compared the two groups, they found that the women who were asymptomatic were generally fitter, and had fewer and smaller tumours in their brains. They also found that women who were diagnosed with brain metastases before symptoms had developed tended to have less aggressive treatments and to live longer (an average of 10.4 months compared to 6.9 months).

The researchers also looked at different types of breast cancer. In patients that had a type of breast cancer called HER2-positive, the researchers found that the average survival in women without symptoms was 15.2 months, compared to 11.5 months for women with symptoms.

Laakmann said: "Overall, these results suggest that women may be better off if their brain metastases are diagnosed before they begin to cause symptoms. It could be that the asymptomatic women are being diagnosed at an earlier stage, which we would expect to increase survival time, the smaller size and number of brain metastases could also be factors.

"We now need to carry out a clinical trial to see what happens if we screen high-risk breast cancer patients for brain metastases. This will verify whether doing so could increase survival, symptom control or quality of life."

Professor David Cameron from the University of Edinburgh, UK, is a member of 12th European Breast Cancer Conference organizing committee and was not involved in the research. He said: "Despite major improvements in the treatments available for breast cancer patients, we have very few good treatments for when the cancer spreads to the brain. We need to know a lot more about how breast cancer spreads to the brain and what we can do to help this groups of patients.

"This study is important because it suggests there could be benefit in trying to diagnose brain metastases early, rather than waiting to see who develops symptoms. We already have the technology to do this, so what we now need to understand is whether in diagnosing spread to the brain earlier, we truly influence the outcomes, or just result in patients living longer with the knowledge of their brain metastases, an effect known as 'lead time bias'. Careful studies will be needed, and we will be better informed if we can also understand better which patients have a high risk of developing this devastating complication of breast cancer."

For more information: www.eortc.be 

Related Content

News | Artificial Intelligence | May 11, 2021
May 11, 2021 — Whiterabbit, an AI technology company focused on early...
News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
Research finds that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening

Getty Images

News | Lung Imaging | May 05, 2021
May 5, 2021 — Lung cancer is the third most common cance
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | May 03, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
Despite receiving high radiation doses to their tumors, lung cancer patients treated with technique that spares a large part of the esophagus did not develop severe inflammation of the esophagus

Getty Images

News | Lung Imaging | April 30, 2021
April 30, 2021 — For many patients with localized lung cance...